Analyst Expects Approval for Amarin; Reiterates $21 Price Target
(Thomson Reuters ONE) -
In a note to clients, Roth Capital Partner's Joseph Pantginis, Ph.D told
investors that his firm expects full approval of Amarin Corporation's
(NASDAQ:AMRN) AMR101 on or about this Thursday's PDUFA date.
The firm is maintaining their Buy rating and $21 price target for shares of the
stock which closed the day at $15.15 -0.01 (-0.07%).
"We recommend owning Amarin based on 1) the commercial potential of AMR101
defined by differentiated Phase III data from the ANCHOR and MARINE studies as
well as 2) the potential upside from a takeout or major partnership," wrote
Pantginis.
In the note, Pantginis discusses various post-approval scenarios for AMRN, but
believes the most likely scenario is a takeout of the company.
"Potential suitors, who have likely been waiting in the wings, have been waiting
for 1) the receipt of patent protection (happening) and 2) potential NCE status
around the approval," states Pantginis.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1628753]
Datum: 23.07.2012 - 22:55 Uhr
Sprache: Deutsch
News-ID 167825
Anzahl Zeichen: 1596
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Analyst Expects Approval for Amarin; Reiterates $21 Price Target"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
